Literature DB >> 20184307

Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature.

Zhaofei Liu1, Bing Jia, Jiyun Shi, Xiaona Jin, Huiyun Zhao, Fang Li, Shuang Liu, Fan Wang.   

Abstract

Integrin αvβ3 has been well-documented as one of the key players in the process of tumor angiogenesis. Radiolabeled RGD (Arg-Gly-Asp) peptides that specifically target integrin αvβ3 have great potential for tumor early detection and noninvasively monitoring the status of tumor angiogenesis. We developed a cyclic RGD dimeric probe (99m)Tc-HYNIC-Gly3-E[PEG4-c(RGDfK)]2 ((99m)Tc-G3-2P4-RGD2) (using tricine and TPPTS as the coligands, TPPTS = trisodium triphenylphosphine-3,3',3''-trisulfonate), and investigated whether it could be used to noninvasively visualize and quantify integrin αvβ3 expression in vivo. HYNIC-Gly3-E[PEG4-c(RGDfK)]2 was synthesized and labeled with (99m)Tc. The biodistribution and planar γ-imaging studies of (99m)Tc-G3-2P4-RGD2 were performed in both U87MG (human integrin αvβ3 positive/murine integrin αvβ3 positive) and HT-29 (human integrin αvβ3 negligible /murine integrin αvβ3 positive) tumor-bearing nude mouse models. The correlation of (99m)Tc-G3-2P4-RGD2 tumor uptake values (measured by ex vivo biodistribution) with expression levels of human integrin αvβ3 or murine integrin αvβ3 (measured by Western blot) were determined in U87MG and HT-29 tumor models, respectively. (99m)Tc-G3-2P4-RGD2 exhibited increased receptor binding affinity and in vivo tumor uptake as compared with previously reported RGD dimeric tracer (99m)Tc-RGD2 (without Gly3 and PEG4 spacers). The tumor uptake of (99m)Tc-G3-2P4-RGD2 was related to the expression levels of both human integrin αvβ3 (expressed on tumor cells) and murine integrin αvβ3 (expressed on newborn tumor vasculature). Our results demonstrate that (99m)Tc-G3-2P4-RGD2 is a useful agent for integrin αvβ3 imaging. The relationship between (99m)Tc-G3-2P4-RGD2 uptake and integrin αvβ3 expression level as determined by this study would provide useful information for clinical translation of RGD probes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20184307     DOI: 10.1021/bc900547d

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  19 in total

1.  Inter-heterogeneity and intra-heterogeneity of αvβ3 in non-small cell lung cancer and small cell lung cancer patients as revealed by 68Ga-RGD2 PET imaging.

Authors:  Fei Kang; Zhe Wang; Guoquan Li; Shengjun Wang; Daliang Liu; Mingru Zhang; Mingxuan Zhao; Weidong Yang; Jing Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-12       Impact factor: 9.236

2.  Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ3 and vascular endothelial growth factor.

Authors:  Xianlei Sun; Teng Ma; Hao Liu; Xinhe Yu; Yue Wu; Jiyun Shi; Bing Jia; Huiyun Zhao; Fan Wang; Zhaofei Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

3.  Noninvasive detection of human-induced pluripotent stem cell (hiPSC)-derived teratoma with an integrin-targeting agent (99m)Tc-3PRGD2.

Authors:  Yang Li; Zhaofei Liu; Chengyan Dong; Peng He; Xujie Liu; Zhaohui Zhu; Bing Jia; Fang Li; Fan Wang
Journal:  Mol Imaging Biol       Date:  2013-02       Impact factor: 3.488

4.  Differential diagnosis of solitary pulmonary nodules using ⁹⁹mTc-3P₄-RGD₂ scintigraphy.

Authors:  Qingjie Ma; Bin Ji; Bing Jia; Shi Gao; Tiefeng Ji; Xueju Wang; Zhenguo Han; Guoqing Zhao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-27       Impact factor: 9.236

Review 5.  Advances in Clinical Oncology Research on 99mTc-3PRGD2 SPECT Imaging.

Authors:  Liming Xiao; Jun Xin
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

6.  Synthesis and evaluation of a new bifunctional NETA chelate for molecular targeted radiotherapy using(90)Y or(177)Lu.

Authors:  Chi Soo Kang; Yunwei Chen; Hyunbeom Lee; Dijie Liu; Xiang Sun; Junghun Kweon; Michael R Lewis; Hyun-Soon Chong
Journal:  Nucl Med Biol       Date:  2014-10-20       Impact factor: 2.408

7.  Specific uptake of 99mTc-NC100692, an αvβ3-targeted imaging probe, in subcutaneous and orthotopic tumors.

Authors:  Jason L J Dearling; Jessica W Barnes; Dipak Panigrahy; Robert E Zimmerman; Frederic Fahey; S Ted Treves; Matthew S Morrison; Mark W Kieran; Alan B Packard
Journal:  Nucl Med Biol       Date:  2013-05-20       Impact factor: 2.408

8.  Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT.

Authors:  Yang Zhou; Sudipta Chakraborty; Shuang Liu
Journal:  Theranostics       Date:  2011-01-18       Impact factor: 11.556

9.  Evaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability.

Authors:  Jiyun Shi; Yang Zhou; Sudipta Chakraborty; Young-Seung Kim; Bing Jia; Fan Wang; Shuang Liu
Journal:  Theranostics       Date:  2011-07-25       Impact factor: 11.556

10.  Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.

Authors:  Jiyun Shi; Di Fan; Chengyan Dong; Hao Liu; Bing Jia; Huiyun Zhao; Xiaona Jin; Zhaofei Liu; Fang Li; Fan Wang
Journal:  Theranostics       Date:  2014-01-18       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.